

# **A Possible Role in Immune Response Modulation after Autologous Bone Marrow Stem Cell Transplantation in Type 1 DM**

**Thesis**

Submitted for partial fulfillment of M.D degree  
in **Internal Medicine**

**By**

**Hanan Mahmoud Ali Mahmoud**

M.B.B.Ch., and Master Degree of Internal Medicine  
Faculty of Medicine - Ain Shams University

**Under Supervision of**

**Prof. Mohamed Fahmy Abd El Aziz**

Professor of Internal Medicine  
Faculty of Medicine – Ain Shams University

**Prof. Abdel Sattar El Deeb**

Professor of Internal Medicine  
Faculty of Medicine – Ain Shams University

**Prof. Alaa El Din Ismail**

Professor of General Surgery  
Faculty of Medicine – Ain Shams University

**Prof. Hala Ahmed Talkhan**

Professor of Clinical Pathology  
Faculty of Medicine – Ain Shams University

**Dr. Khaled Mahmoud Makboul**

Assistant Professor of Internal Medicine  
Faculty of Medicine – Ain Shams University

**Faculty of Medicine  
Ain Shams University**

**2014**



وَأَنْزَلَ اللَّهُ عَلَيْكَ  
الْكِتَابَ وَالْحِكْمَةَ  
وَعَلَّمَكَ مَا لَمْ تَكُنْ  
تَعْلَمُ وَكَانَ فَضْلُ  
اللَّهِ عَلَيْكَ عَظِيمًا  
صَدَقَ اللَّهُ الْعَظِيمُ

سورة  
النساء الآية (113)

## Acknowledgements

First, and foremost, my deepest gratitude and thanks should be offered to **"ALLAH"**, the Most Kind and Most Merciful, for giving me the strength to complete this work.

I would like to express my sincere gratitude to **Prof. Mohamed Fahmy Abd El Aziz**, Prof. of Internal Medicine, Faculty of Medicine – Ain Shams University, for his continuous support and guidance for me to present this work. It really has been an honor to work under his generous supervision.

I acknowledge with much gratitude to **Prof. Abdel Sattar El Deeb**, Prof. of Internal Medicine, Faculty of Medicine – Ain Shams University, for his great supervision and unlimited help to provide all facilities to accomplish this work.

I acknowledge with much gratitude to **Prof. Alaa El Din Ismail**, Prof. of General Surgery, Faculty of Medicine – Ain Shams University, for his great supervision, valuable advice in this work.

I would like also to thank with all appreciation **Prof. Hala Ahmed Talkhan**, Prof. of Clinical Pathology, Faculty of Medicine – Ain Shams University, for her assistance and cooperation in this work.

I can't forget to thank **Dr. Khaled Mahmoud Makboul**, Assistant Professor of Internal Medicine, Faculty of Medicine – Ain Shams University, for his encouragement and great help during the whole work.

# List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations .....	i
List of Tables .....	vi
List of Figures .....	vii
Introduction.....	1
Aim of the Work.....	8
Review of Literature	
- Diabetes Mellitus .....	9
- Immune Mediated Beta Cell Destruction in Type 1 DM.....	33
- Stem cells .....	48
- Immunomodulation and HSCs Therapy in type 1 DM.....	85
Patients and Methods.....	105
Results.....	121
Discussion .....	131
Conclusion .....	141
Recommendation.....	142
Summary .....	143
References.....	146
Arabic Summary .....	—

## **List of Abbreviations**

<b>AAs</b>	: Antibodies to islet autoantigens
<b>ACE</b>	: Angiotensin-converting enzyme
<b>AD</b>	: Autoimmune disease
<b>ADA</b>	: American Diabetes Association
<b>ADSCs</b>	: Adipose tissue derived stromal cells
<b>AGEs</b>	: Advanced glycation end products
<b>AHSCT</b>	: Hematopoietic stem cell transplantation
<b>ALL</b>	: Acute lymphoblastic leukemia
<b>ALT</b>	: Alanine Amino transferase
<b>AML</b>	: Acute myeloid leukemia
<b>APC</b>	: Antigen-presenting cells
<b>ARBs</b>	: Angiotensin receptor blockers
<b>ASCs</b>	: Adult stem cells
<b>ASCT</b>	: Autologous stem cell transplantation
<b>ASL</b>	: Amyotrophic lateral sclerosis
<b>AST</b>	: Aspartate Amino transferase
<b>BM</b>	: Bone marrow
<b>BR</b>	: Breast cancer
<b>BW</b>	: Balance Weight
<b>CBC</b>	: Complete blood count
<b>CHD</b>	: Chronic heart disease
<b>CLL</b>	: Chronic lymphocytic leukemia
<b>CML</b>	: Chronic myeloid leukemia
<b>CNS</b>	: Central nervous system
<b>CRC</b>	: Colorectal cancer
<b>CRP</b>	: C-reactive protein

---

## **List of Abbreviations** *(Cont...)*

<b>CV</b>	: Cardiovascular
<b>CVD</b>	: Cardiovascular disease
<b>CY</b>	: Cyclophosphamide
<b>DAG</b>	: Diacylglycerol
<b>DCCT</b>	: Diabetes control clinical trial
<b>DCs</b>	: Activated dendritic cells
<b>DCs</b>	: Dendritic cells
<b>DKA</b>	: Diabetic ketoacidosis
<b>DLI</b>	: Donor's lymphocyte infusion
<b>DM</b>	: Diabetes mellitus
<b>DMARDs</b>	: Disease-modifying anti-rheumatic drugs
<b>DMD</b>	: Duchenne muscular dystrophy
<b>DOPA</b>	: Dopamine precursor
<b>DPP-4</b>	: Dipeptidyl peptidase-4 inhibitors
<b>EBMT</b>	: European Bone Marrow Transplantation
<b>EF</b>	: Ejection fraction
<b>ESCs</b>	: Embryonic stem cells
<b>FISH</b>	: Fluorescence in situ hybridization
<b>FISH</b>	: Fluorescence in situ hybridization
<b>FPG</b>	: Fasting plasma glucose
<b>GAD</b>	: Glutamic acid decarboxylase
<b>GAPDH</b>	: Glyceraldehyde 3-phosphate dehydrogenase
<b>G-CSF</b>	: Granulocyte colony-stimulating factor
<b>GD</b>	: Gestational Diabetes
<b>GFAT</b>	: Glucosamine-glutamine, fructose-6-phosphate amidotransferase

---

## **List of Abbreviations** *(Cont...)*

<b>GLUTs</b>	: Glucose transporters
<b>GSH</b>	: Glutathione
<b>GVHD</b>	: Graft-versus-host disease
<b>GVT</b>	: Graft versus tumor
<b>HbA1c</b>	: Haemoglobin A1C
<b>HCL</b>	: Hydrochloric acid
<b>HD</b>	: Huntington's disease
<b>HDC</b>	: High dose chemotherapy
<b>HHS</b>	: hyperosmolar hyperglycemic state
<b>HLA</b>	: Human leukocyte antigen
<b>HSCs</b>	: Haematopoietic stem cells
<b>ICA</b>	: Islet cell antibody
<b>ICM</b>	: Inner cell mass
<b>IFG</b>	: Impaired fasting BG
<b>IFN- <math>\gamma</math></b>	: gamma interferon
<b>IgG</b>	: Immunoglobulin G
<b>IHA</b>	: Immune haemolytic anemia
<b>IL</b>	: Interleukin
<b>ITP</b>	: Immune thrombocytopenia purpura
<b>JIA</b>	: Juvenile idiopathic arthritis
<b>KLAT</b>	: Keratolimbic allograft transplantation
<b>LC</b>	: Lung cancer
<b>LDH</b>	: Lactate dehydrogenase
<b>LSCD</b>	: Limbal SC deficiency
<b>MAPK</b>	: Mitogen-activated protein kinase

---

## **List of Abbreviations** *(Cont...)*

<b>MF</b>	: Macrophages
<b>MHC</b>	: Major histocompatibility complex
<b>MI</b>	: Myocardial infarction
<b>Mo</b>	: Monocytes
<b>MODY</b>	: Maturity-onset diabetes of the young
<b>MS</b>	: Multiple Sclerosis
<b>MSC</b>	: Mesenchymal stem cells
<b>NADPH</b>	: Nicotinamide adenine dinucleotide phosphate
<b>NF</b>	: Nuclear factor
<b>NOD</b>	: Non-obese diabetic
<b>OA</b>	: Osteoarthritis
<b>OC</b>	: Ovarian cancer
<b>OGTT</b>	: Oral glucose tolerance test
<b>PCR</b>	: Polymerase chain reaction
<b>PD</b>	: Parkinson's disease
<b>PD</b>	: Processing Disposable(s)
<b>PDGF</b>	: Platelet-derived growth factor
<b>PMN</b>	: Polymorphonuclear
<b>PPMS</b>	: Primary progressive MS
<b>RA</b>	: Rheumatoid arthritis
<b>RAGE</b>	: Receptor for AGE
<b>RCC</b>	: Renal cell cancer
<b>RICT</b>	: Reduced intensity conditioning regimens
<b>RIST</b>	: Reduced-intensity SC transplantation
<b>ROS</b>	: Reactive oxygen species
<b>SC</b>	: Cesarean section

---



## **List of Abbreviations** *(Cont...)*

<b>SCLC</b>	: Small cell lung carcinoma
<b>SDH</b>	: Sorbitol dehydrogenase
<b>SF</b>	: Synovial fluid
<b>SLE</b>	: Systemic lupus erythematosus
<b>SPMS</b>	: Secondary progressive MS
<b>SSc</b>	: Systemic sclerosis
<b>T1DM</b>	: Type 1 diabetes mellitus
<b>Th</b>	: T helper
<b>TLRs</b>	: Toll-like receptors
<b>TMB</b>	: Tetra methyl benzidine
<b>TNF</b>	: Tumour necrosis factor
<b>TNF-<math>\beta</math></b>	: Tumor necrosis factor beta
<b>TZDs</b>	: Thiazolidinediones
<b>UCB</b>	: Umbilical cord blood
<b>UCE</b>	: Umbilical cord blood
<b>UCE</b>	: Umbilical cord epithelium
<b>UTI</b>	: Urinary tract infection
<b>2hPG</b>	: 2-hour plasma glucose
<b><math>\alpha</math></b>	: Alpha
<b><math>\beta</math></b>	: Beta
<b><math>\gamma</math></b>	: Gamma

---

## List of Tables

Table No.	Title	Page No.
<u>Review of Literature:</u>		
<b>Table (1):</b>	Recommendations for the diagnosis and classification of diabetes mellitus 2013.....	12
<b>Table (2):</b>	Criteria for testing for diabetes in asymptomatic individual .....	13
<b>Table (3):</b>	Gestational diabetes mellitus GDM .....	13
<b>Table (4):</b>	Advantages and Disadvantages of Screening Tests for Diabetes .....	14

---

## List of Tables *(Cont...)*

Table No.	Title	Page No.
<u>Results:</u>		
<b>Table (1):</b>	Descriptive data of studied subjects as regard: age, weight, BMI, systolic and diastolic blood pressure, duration of type 1 DM, total insulin requirement. ....	121
<b>Table (2):</b>	Sex distribution in studied subjects. ....	122
<b>Table (3):</b>	Liver function tests (pre transplantation): ....	122
<b>Table (4):</b>	Kidney function tests (pre transplantation): ....	122
<b>Table (5):</b>	Complete Blood Picture (pre transplantation):.....	123
<b>Table (6):</b>	Change in total insulin requirement after transplantation.....	124
<b>Table (7):</b>	Fasting blood sugar:.....	125
<b>Table (8):</b>	Post prandial blood sugar. ....	126
<b>Table (9):</b>	HbA1c.....	127
<b>Table (10):</b>	C-peptide .....	128
<b>Table (11):</b>	Interleukin 4.....	129
<b>Table (12):</b>	Gamma interferon.....	130

## List of Figures

Figure No.	Title	Page No.
<u>Review of Literature:</u>		
<b>Figure (1):</b>	Schematic diagram of immune cells reported in human type 1 diabetes mellitus (T1DM) pathogenesis .....	38
<b>Figure (2):</b>	(a) IFN- $\gamma$ monomer. (b): INF- $\gamma$ dimer .....	40
<b>Figure (3):</b>	IL-4 structure has a compact, globular fold (similar to other cytokines), stabilised by 3 disulphide bonds .....	45
<b>Figure (4):</b>	Embryonic stem cells.....	52
<b>Figure (5):</b>	Adult stem cells .....	55
<b>Figure (6):</b>	Processing disposable .....	108
<b>Figure (7):</b>	The Harvest instrument.....	109
<b>Figure (8):</b>	Bone marrow aspirate after separation of mononuclear layer .....	110
<b>Figure (9):</b>	Withdraw remaining plasma into syringe with blunt needle .....	111

## List of Figures *(Cont...)*

Figure No.	Title	Page No.
<u>Results:</u>		
<b>Figure (1):</b>	Change in total insulin requirement after transplantation.....	124
<b>Figure (2):</b>	Fasting blood sugar pre and after transplantation 3 and 6 month.....	125
<b>Figure (3):</b>	Post prandial blood sugar pre and after transplantation 3 and 6 months. ....	126
<b>Figure (4):</b>	HbA1C pre and after transplantation 3 and 6 months. ....	127
<b>Figure (5):</b>	C-peptide pre and after transplantation 3 months and 6months.....	128
<b>Figure (6):</b>	Interleukin 4 pre and after transplantation 2, 4, 6 months. ....	129
<b>Figure (7):</b>	Gamma interferon pre and after transplantation 2, 4, 6 months.....	130

---

# Introduction

Type 1 DM comprises only 5% to 10% of all diabetic etiologies but is associated with a high frequency of vascular complications and compromises quality and expectancy of life (*Rubin and Peyrot, 1999*). Combination of genetic, immunologic, and non genetic factors contributes to the onset and progression of Type 1 DM (*Atkinson and Maclaren, 1994; Lipton et al., 1992*). Specific HLA antigens, in particular DR3 and DR4, have been associated with increased risk for Type 1 DM development (*Lipton et al., 1992; Barbesion et al., 1997*), while DR2 alleles generally have been described as "protective" of Type 1 DM (*Thorsby and Ronningen 1993*). In addition to HLA predisposing factors, viral infection, psychological factors, and dietary factors have been described as predisposing factors (*Beyhum et al., 1997; Robinson and Fuller, 1985*).

Pathologically autoimmune diabetes is characterized by mononuclear cell infiltration into the pancreatic islets, termed insulinitis. These mononuclear cells consists of CD4 + and CD8+ T cells, B cells, NK cells, and macrophages (*Kawamoto et al., 2001*). B-cells are among the earliest cells to infiltrate the pancreatic islets of NOD mice, and auto antibodies against islet antigens indicate disease onset in humans and mice. Despite this, autoantibody production is not sufficient to initiate disease and is disconnected from the occurrence of diabetes and insulitis (*Lehuen et al., 1990*). Rather, B-cells are multifunctional and are crucial antigen-presenting cells (APCs)

for priming proinflammatory T-cell responses to  $\beta$ -cell antigens (*Bouaziz et al., 2007*) Transient B-cell depletion after the first signs of disease onset using anti-BLyS mAb also arrests diabetes progression and maintains NOD mice in a “honeymoon” state for extended periods (*Zekavat et al., 2008*). However, in general, T lymphocytes play the most pivotal role in initiating the disease process (*Sempe et al., 1991*).

In 1986, *Mosmann et al* reported that upon activation CD4<sup>+</sup> T cells will differentiate into two distinct T helper (Th) cell clones expressing distinct cytokine profiles and effector functions, thus giving rise to a unifying Th1/Th2 paradigm. Central to this are the specific requirements for induction of Th1 and Th2 activities, including the nature of APC (macrophages, dendritic cells, or B cells) (*Macatonia et al., 1993; Duncan and Swain 1994*), strength of TcR binding to processed antigen, and Th1 and Th2 cytokines (*Romagnani, 1995*). Th1 cells produce IL-2 and gamma interferon (IFN-  $\gamma$ ), while Th2 cells produce IL-4, IL-5, IL-10, and IL-13 (*Robinson and Fuller, 1985*).

Th0 cells, which produce both Th1 and Th2 cytokines, are generally regarded as precursors for Th1 and Th2 cells, being swayed into differentiating into either pathway in response to external stimuli and also in response to Th1 and Th2 cytokines (*Swain et al., 1990; Sad and Mosmann 1994*).

Th1 cytokines induce Th1 activity and block Th2 activity (*Hsieh et al., 1993*), whereas Th2 cytokines promote Th2

---